CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Marijuana +2 moredrug
Likely dose
Quetiapine 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00743366
NCT00743366Phase 2Completed
CompareCT.gov

Effect of Quetiapine on Marijuana Withdrawal and Relapse

New York State Psychiatric Institute·interventional·Posted Aug 28, 2008·Updated Aug 18, 2017

In Brief

A Phase 2 clinical trial evaluating Marijuana, Quetiapine, and 1 other intervention for Marijuana Smoking. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The objective of this study is to investigate the interaction between marijuana and quetiapine, with the goal of using this information to improve marijuana treatment outcome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMarijuana Smoking
CountriesUnited States
CollaboratorsResearch Foundation for Mental Hygiene, Inc., National Institute on Drug Abuse (NIDA)

Timeline

Phase 2CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 28, 2008
Enrollment StartAug 1, 2008
Primary CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 17.8 years ago

Interventions

Marijuanadrug

0,6.2% THC

Quetiapinedrug

200 mg/day

Placebo oral capsuledrug